Phase II Trial of the PARP1 Inhibitor, Niraparib, in BAP1 and other DNA Damage Response (DDR) Pathway Deficient Neoplasms

Purpose

The primary objective is to determine the response rate for subject with mutations in BAP1 and other genes involved in the DNA damage response pathway.

Inclusion Criteria:

  • Age ≥18 years
  • Histologically confirmed diagnosis of incurable cancer
  • Prior treatment with standard systemic therapy (must have exhausted or declined all known effective therapies)
  • Must be willing to provide blood/serum/plasma for toxicity monitoring and other research purposes
  • Must have formalin-fixed paraffin embedded (FFPE) tissue available for research purposes. Tissue must have been obtained within the last 3 years
  • Measurable disease by RECIST (v 1.1) criteria
  • Adequate organ function
  • ECOG Performance Status of 0-2
  • Life expectancy ≥ 12 weeks
  • Women of childbearing potential must have a negative serum pregnancy test within 7 days prior to the first dose
  • Confirmed diagnosis of uveal melanoma, mesothelioma, renal cell carcinoma (clear cell subtype), or cholangiocarcinoma (Cohort A only)
  • Known DNA damage repair mutation including any one of the following: ARID1A, ATM, ATR, BACH1 (BRIP1), BAP1, BARD1, BLM, CHEK1, CHEK2, CDK2, CDK4, ERCC, FAM175A, FEN1, IDH1, IDH2, MRE11A, NBN (NBS1), PALB2, POLD1, PRKDC (DNA-PK) PTEN, RAD50, RAD51, RAD52, RAD54, RPA1, SLX4, WRN, or XRCC. Only CLIA certified next generation sequencing (NGS) assays are acceptable. Variants of unknown significance (VUS) will be allowed to enroll on study (Cohort B only)
  • Subjects must agree to not donate blood during the study or for 90 days after the last dose of study treatment.
  • Subjects receiving corticosteroids may continue as long as their dose is stable for least 4 weeks prior to initiating protocol therapy.

Gender

N/A

Monetary compensation

No

Can be done from home

No

Keywords

Cholangiocarcinoma, Renal cancer, Melanoma, mesothelioma

Principal Investigator

Thomas J George, Jr, M.D.

Contact Information

tgeorge@ufl.edu

352-273-8008


Be an Informed Participant

Before deciding to participate in a research study, take time to learn about clinical research, how it's conducted and your rights as a research participant. Following are some helpful resources from independent sources. Always remember that a clinical research study is research, not treatment.

Know Who to Contact

  • Eligibility: For questions about a specific study and who is eligible to participate, call or email the contact person listed for that study.
  • Your Rights: For questions about your rights as a research participant, contact the UF Institutional Review Boards at 352-273-9600.
  • Feedback: For general questions or feedback about study listings, email the UF Clinical and Translational Science Institute at CTSI-Studies-L@lists.ufl.edu.

Other Resources

  • HealthStreet: Health-focused services, classes and events, and opportunities to participate in research.
  • ResearchMatch.org: Join a national registry of volunteers willing to be contacted about research studies.

For Research Teams